Omega Therapeutics — Investor Presentation (January 2024)
44 slides from Omega Therapeutics's investor presentation, Jan 5, 2024
Slide 1: Transforming Medicine Through Precision Epigenomic Control
Q OMEGA Ine A PiU Ties Transforming Medicine Through Precision Epigenomic Control Programmable mRNA Therapeutics January 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-look
Slide 3: Omega Therapeutics: A Clinical-Stage Company Pioneering a New Class of Medicines
Omega Therapeutics: A Clinical-Stage Company Pioneering a New Class of Programmable Epigenomic mRNA Medicines J 7, YS | CLINICAL PROOF-OF-PLATFORM ESTABLISHED WORLD-CLASS LEADERSHIP Preliminary data forlead Pre-transcriptional Diverse pipeline spanning Deeply experienced programin HCC showed gene ex
Slide 4: OMEGA Platform Engineers Programmable mRNA Therapeutics
OMEGA Platform Engineers Programmable mRNA Therapeutics Gene TECHNOLOGY Epigenomic Controllers BIOLOGY New Drug Targets Epigenomic Controller Epigenomic ‘sector , Numer DNA-binding domain * mRNA expresses a fusion protein consisting of: — DNA-binding domain for site-specific targeting — Epigenomic e
Slide 5: Omega's Controlled Epigenomic Modulation Approach is a Significant Technological Advance
Omega’s Controlled Epigenomic Modulation Approach is a Significant Technological Advance Existing modalities have limitations + Restricted to druggable target structures * Can only address narrow therapeutic areas * Constrained to direct PK/PD relationship with associated concerns for safety / thera
Slide 6: Broad Applicability Across Nearly All Diseases and Human Genes
Broad Applicability Across Nearly All Diseases and Human Genes DISEASE PROCESSES Neoplasia Metabolic Dysregulation Fibrotic Processes immune Dysfunction Vascular Pathology Tissue Degeneration Sample of Genes Targetable by OMEGA Platform (Non-Exhaustive) Ey ONCOLOGY CTNNB1 HCC. melanoma, endometrial,
Slide 7: Preclinical Proof-of-Concept Established Across Diverse Therapeutic Areas
Preclinical Proof-of-Concept Established Across Diverse Therapeutic Areas ——— CLINICAL INDICATION DISCOVERY PRECLINICAL PARTNER GENE(S) Phase 1/2 Phase 3 (or%-2002) Hepatoceltar Phase 1/2 MYCHELANGELO™ | Study Oncology (ont 01) aaa IND-Enabling Studies Ongoing Undisclosed Multiple | Inflammation / o
Slide 8: Lead Program Overview
Lead Program Overview OTX-2002 for MYC-HCC Q OMEGA’ THERAPEUTICS
Slide 9: MYC: The Holy Grail of Master Oncogenes
MYC: The Holy Grail of Master Oncogenes « Primary driver of cancer growth and immune evasion in more than 50% of human cancers * Strongly correlated with metastases and poor patient prognosis ¢ Historically ‘undruggable’ due to its disordered protein structure and autoregulation ¢ Potential solution
Slide 10: OTX-2002 Mechanism of Action
OTX-2002 Mechanism of Action Preclinical Data Confirms Proof-of-Concept Through Epigenetic Modulation of MYC OQ sito spocite target engagement A @ Site-specific cad epigenetic state _ 075 change(in vitro) 3 3 £050 2 2 é 0.25 0.00 amon ‘Genomic coordinates Site-specific epigenetic change and reductio
Slide 11: OTX-2002 Results in Rapid and Durable Downregulation of MYC Expression
OTX-2002 Results in Rapid and Durable Downregulation of MYC Expression and Reduces Viability of HCC Cancer Cells Preclinically Hep3B * OTX-2002 is designed to target a specific EpiZip in order to downregulate —s—MYC mRNA MYC expression —*— Cell Viability 100 - «-MYC Protein + Rapid and durable downr
Slide 12: OTX-2002 Selectively Modulates Cancer Cells without Impacting Normal Primary Cells
OTX-2002 Selectively Modulates Cancer Cells without Impacting Normal Primary Cells in Preclinical Models Cancer cells Normal cells 120 120 z z 2 100 2 100 iJ £ 5 80 5 80 .-) r) é x = 60 = 60 2 2 5 5 S 40 S 40 > > 3 3 o 20 @ OTX-2002 oO 20 @ OTX-2002 m Negative control m Negative control 0+ ot 0 0.00
Slide 13: OTX-2002 Demonstrated Statistically Significant Inhibition of Tumor Growth
OTX-2002 Demonstrated Statistically Significant Inhi in Preclinical Models ion of Tumor Growth HCC Subcutaneous Tumor Model (Hep3B) No Significant Impact on Body Weight in Mice 1000 = 2 —e—Negative Control eS ® —=-OTX-2002 & o 800 —+-Small Molecule & = Comparator a 10 = s 600 3 2 0 $ é 5 400 2 & = —
Slide 14: OTX-2002 Demonstrated Combination Benefit with Checkpoint Inhibitors
OTX-2002 Demonstrated Combination Benefit with Checkpoint Inhibitors in Preclinical Models HCC Tumor Model (Hepa1-6) 2500 > Control HEC —e Anti-PD-L1 2000 eo Anti-PD1 —e-EC + PDL = 2 EC +aPD1 é 1500 EH = 1000 5 2 500 0 P<0.0001 0 5 10 18 20 25 Day 30 6 Change in Body Weight (%) No Significant Impact
Slide 15: MYC-Targeting EC Conferred Long-Term, Tumor-Specific Immune Memory
MYC-Targeting EC Conferred Long-Term, Tumor-Specific Immune Memory as Monotherapy and in Combination with Anti-PD1 in Preclinical Models immunocompetent HCC Subcutaneous Tumor Model (Hepa 1-6) = PBS + muMYC EC (3 mg/kglV Q5D) #- Anti-PD1 (10 mgikg IP BIW) Tumor volume (mm?) 500 0 3 10 5 20 2 30 + An
Slide 16: MYCHELANGELO I: Preliminary Clinical Data for OTX-2002
MYCHELANGELO™ | Preliminary Clinical Data for OTX-2002 Announced September 2023 Q OMEGA’ THERAPEUTICS
Slide 17: MYCHELANGELO I: Ongoing Phase 1/2 Clinical Trial of OTX-2002 in HCC
MYCHELANGELO™ |: Ongoing Phase 1/2 Clinical Trial of OTX-2002 in HCC* Global Two-Part Study of OTX-2002 as Monotherapy and in Combination with Standard of Care** OTX-2002: IV dosing, once-every-two-weeks; Patients to be enrolled across U.S., Asia, and Europe Dose Escalation HCC Expansion Part 1: ad
Slide 18: Encouraging Emerging Safety Profile for OTX-2002 From First Two Cohorts
Encouraging Emerging Safety Profile for OTX-2002 From First Two Cohorts* Phase 1 Study Enrolled Difficult-to-Treat, Heavily Pretreated Population Demographics ate ge ck + OTX-2002 was generally well tolerated - with no DLTs; MTD not reached , Soft Tissue Sarcoma 78/ F / White 3 ee) + Majority of AEs
Slide 19: Predictable Pharmacokinetics with Rapid Clearance of Drug Product Observed
Predictable Pharmacokinetics with Rapid Clearance of Drug Product Observed Clinical Pharmacokinetics and Lack of Immunogenicity Directly Translate from Preclinical Experience 10 —* Dose Level 1 a Dose Level 2 a4 5 * OTX-2002 was cleared rapidly from systemic LNP 2 od circulation Ss ay |_“ 3 + No acc
Slide 20: Highly-Specific Target Engagement and Intended Epigenetic State Change
Highly-Specific Target Engagement and Intended Epigenetic State Change at Target Genomic Loci within MYC IGD Observed * Dose-dependent, on-target increase in cell-free DNA MYC methylation signal; persistent over two-week dosing cycle Target Ex OTX-2002 Dose EpiZip ~ we Pre-Dose Vv Day 3 Day 8 Day 15
Slide 21: Rapid, Robust & Durable Downregulation of MYC mRNA Expression Observed
Rapid, Robust & Durable Downregulation of MYC mRNA Expression Observed First Dose Cycle * OTX-2002 reduced MYC mRNA levels in all 8 patients across dose levels 1 and 2 ~* Dose Level 1 © Dose Level 2 — Clinical MYC downregulation consistent with levels that led to robust anti-tumor efficacy in precli
Slide 22: Clinical Data Show Promising Potential of Controlled Epigenomic Modulation
Clinical Data Show Promising Potential of Controlled Epigenomic Modulation Y Highly-specific binding at target genomic loci v Intended epigenetic state change with on-target increase in methylation signature y Rapid, robust and durable downregulation of MYC expression y Encouraging safety and consis
Slide 23: Building Value Through the OMEGA Platform
Building Value Through the OMEGA Platform Sample Data from Other Pipeline Programs THERAPEUTICS
Slide 24: In vivo Proof-of-Concept Data in Oncology Program: MYC-NSCLC
In vivo Proof-of-Concept Data in Oncology Program: MYC-NSCLC OTX-2101 Led to Statistically Significant Inhibition of Tumor Growth in NSCLC Xenograft Tumor Models H460 2000 Negative Control S-OTX-2101 Positive Control 1500 1000 Tumor Volume (mm*) 500 *p=0.05;**p<0.01 O7K-2101 dosed every five days So
Slide 25: MYC-Targeting EC with Immune Checkpoint Enhanced Anti-Tumor Activity in NSCLC
oe Combination of MYC-Targeting EC with Immune Checkpoint Significantly Enhanced Anti-Tumor Activity in Syngeneic Mouse Model of NSCLC Lewis Lung Carcinoma Subcutaneous Tumor Model Survival 2,500 100 —o PBS ia —* Negative Control — MYC EC = _ 2,000 9 anti-PDL1 = 75 € MYC EC + anti-PD-L1 sg & — 1,500
Slide 26: MYC-Targeting EC with EGFR Inhibitor Enhanced Anti-Tumor Activity in NSCLC
oe Combination of MYC-Targeting EC with EGFR Inhibitor Significantly Enhanced Anti-Tumor Activity in Human Xenograft Model of NSCLC H1975 Subcutaneous Tumor Model Survival 2,600), saline 100 —® MYC EC —® osimertinib 2,000 —® MYC EC + osimetinib = =e = 15 Lo £ S is 2 = 1500 = 3 a 2 Ss 50 > 1,000 £ 8
Slide 27: CXCL 1-8-Targeting EC Significantly Decreased Neutrophil Infiltration in Inflamed Lung
CXCL 1-8-Targeting EC Significantly Decreased Neutrophil Infiltration in Inflamed Lung In Vivo Neutrophils cellsimL BALF 8x108 6x105 4x108 2x108 Measurement of Cellular Penetration Into Inflamed Lung — als = EC candidate significantly different compared to disease control, Mann Whitney Normal Diseas
Slide 28: Multigenic Targeting of CXCL1-8 Downregulated Chemokine mRNA Expression
SL | Multigenic Targeting of CXCL1-8 Downregulated Chemokine mRNA Expression and Reduced Neutrophil Migration in Donor Lung Fibroblasts /n Vitro Coordinated Downregulation of mRNA Expression Significant Decrease in Neutrophil Migration Donor1 Donor2 Donor3 1505 @ Control 1255 1255 1255 s Wi CXCL1-8
Slide 29: CXCL 9-11-Targeting EC Reduced mRNA Expression and Protein Levels
CXCL 9-11-Targeting EC Reduced mRNA Expression and Protein Levels in IFNG-Stimulated Primary Human Hepatocytes CXCL9 CXCL10 CXCL11 2 155 g 155 g 155 e e e Ee fz ar £8 104 $8 104 $5 10+~pole ss 3 is 3° 3f @ 23 z= gs £ S854 * 58054 &3 os zi 28 3S 328 2 2 * 27 3 z z Z 00 Z 00 —— Zz 00 E Control EC E Co
Slide 30: HNF4A-Targeting EC Upregulated HNF4a Expression and Reduced Fibrosis Measures
HNF4A-Targeting EC Significantly Upregulated HNF4a Gene Expression and Reduced Key Measures of Fibrosis HNF4a Expression HNF4a Induction Conferred Protection in DDC Fibrosis Model 7 43%" 1 z i 28%* 2 a5 af z £10 38 2 Es EF as 310 =, : 0.0 00 id 05: & s ee x s +DDC Source: Data presented at AASLD 202
Slide 31: SFRP1: Ex vivo Proof-of-Concept in Monogenic Disease Program: Alopecia
SFRP1 Ex vivo Proof-of-Concept in Monogenic Disease Program: Alopecia Downregulation of SFRP1 at 7 Days Post-Treatment with EC Candidate Primary Human Hair Follicle Dermal Papilla (HFDP) Cells 150 + SFRP1 regulates intrafollicular 5 Therapeutic canonical Wnt/B- 9 100 L Hecate catenin activity in 5 r
Slide 32: Understanding the OMEGA Platform
Understanding the OMEGA Platform THERAPEUTICS
Slide 33: Insulated Genomic Domains Are Nature's Control System to Regulate Gene Expression
Insulated Genomic Domains Are Nature’s Control System to Regulate Gene Expression IGDs are the fundamental structural nd functional units for gene control Nature organizes genes in evolutionarily conserved 3D loops of chromatin called Insulated Genomic Domains (IGDs) w% . Ae. T tad Eq, Lung tissue S
Slide 34: OMEGA Platform Interrogates IGD Intervention Points to Determine Optimal Approach
OMEGA Platform Prospectively and Comprehensively Interrogates IGD Intervention Points to Determine Optimal Approach MYC_promoter 40 jos MYC_promoter ab 5 e 6 Dysregulated 2 ,. MYCIGD 3 * a 3 3 ol =} > 2 7 2 MYC_promoter at 10 - ee 5s q Enhancer Densty 2 o[ EC-Treated laN x CTCF sites ltt Minmm \I gz
Slide 35: Unprecedented Epigenomic Control at Pre-transcriptional Level
Unprecedented Epigenomic Control at Pre-transcriptional Level Precise targeting ofa single gene or IGD Exq Specificity robust change in gene expression Bi-directional tuning Controlled and precise Tunability control on magnitude of expression Transient PK with Tailored prospectively engineered durab
Slide 36: Proof-of-Concept Demonstrated Across Diverse Set of Disease Areas
Proof-of-Concept Demonstrated Across Diverse Set of Disease Areas Oncology (MYC HCC) Statistically significant inhibition of HCC tumor growth in vivothrough direct targeting of c-MYC 1000 7 Negative Control —s- OTX.2002 800 600 400 Tumor Volume (mm*) 200 Day “Statistically significant vs negative co
Slide 37: Translation Across Species Demonstrated for EC Mechanism
Translation Across Species Demonstrated for EC Mechanism In-House Data for Both Up and Down Regulation Species Liver Cells Increase in HNF4q Expression in Healthy Liver Tissues (Over and Above Normal Expression) Mouse Nonhuman primate FRG Mouse Mouse (48h) Nonhuman primate (24h) Human (24h) 500 250
Slide 38: Computation-Driven Approach to Expedite Prosecution of New Targets to IND
Computation-Driven Approach to Expedite Prosecution of New Targets to IND DC Selection IND Filing 6-10 months ~18 months (1) interrogate biology (2) Design and initial (3) Optimize clinical candidate (4) IND-enabling work and IGD for target validation of and declare development disease OECs candidat
Slide 39: Initial Programs Leverage Validated LNP Delivery Technologies
Initial Programs Leverage Validated LNP Delivery Technologies OMEGA Platform is Delivery Agonistic; Evaluation Expanding into Other Delivery Modalities Internal Development Efforts to Develop Proprietary LNPs and Expand into Additional Tissues Solid Tumor Local (Intrathecal) (extrahepatic) Conductin
Slide 40: Corporate Summary
Corporate Summary THERAPEUTICS
Slide 41: A World-Class Team to Deliver on Our Vision
A World-Class Team to Deliver on Our Vision Leadership 8 © Mahesh Karande Thomas McCauley President & CEO cso & Novartis Shire {Translate MACROUDE ReNA MekKinsey ‘SCompany Lachemaix | Joshua Reed Ling Zeng Siva Sakham CFO CLAO SVP Tech Ops JPMORGAN it & Quality Ga, Reems vaity on DAinylam ses an ATE
Slide 42: Omega Therapeutics
Omega Therapeutics A Clinical-Stage Company Pioneering a New Class of Programmable Epigenomic mRNA Medicines Programmable epigenomic mRNA medicines designed for pre-transcriptional gene modulation Platform enables rapid prosecution of new targets and IGD biology driven by data science and advanced c
Slide 43: 2024 Priorities and Anticipated Milestones
2024 Priorities and Anticipated Milestones LEAD PROGRAM: OTX-2002 fy WM Continue monotherapy dose escalation in HCC patients & Cohort 3 (0.06 mg/kg): Completed 28-day DLT window & Cohort 4: Commence enrollment in January 2024; dose to be selected within range of 0.09 - 0.125 mg/kg Q Protocol provide
Slide 44: Thank You
Q OMEGA Taber AP Es@PT Gas Thank You
Omega Therapeutics — Investor Presentation (January 2024) on 6ix